Search Results for “Shire ” – media

Takeda, Japanese pharma giant clinched to Buy Shire for $61.50 billion

On Monday Takeda Pharmaceutical confirmed to acquire Shire for £45.3 billion ($61.50 billion). The final deal will be 46 percent cash and 54 percent stock.
- Source: business standard
- 688
- May 9, 2018
Market Views merger-and-acquisition Shire Takeda
Takeda reaches preliminary deal to buy Shire for close to $65B

Takeda has upped its offer to buy Shire $SHPG for a mix of stock and cash worth close to $65 billion, which is good enough for the Lexington, MA-based biotech to extend the deadline on their talks to May 8 after determining they were close to finalizing a pact.
- Source: endpts
- 666
- April 25, 2018
Lexington Market Views Shire Takeda
Allergan swoops in as Takeda’s third Shire bid falls short at $61B

Three of Takeda’s anticipated Shire buyout bids have already been rejected—and now, the Japanese drugmaker might just lose out to a competing bidder. Allergan, for instance, is already in talks for a buy.
- Source: fiercepharma
- 510
- April 23, 2018
drugmaker Market Views
Shire——FDA approves VONVENDI® for perioperative management of bleeding in adult patients with von Willebrand disease

Cambridge, Ma. -- Shire plc, the global biotechnology leader in rare disease, today announced the U.S. Food and Drug Administration (FDA) has approved VONVENDI [von Willebrand factor (recombinant)], a recombinant von Willebrand factor (rVWF) treatment for perioperative management of bleeding in adults (age 18 and older) with von Willebrand disease (VWD).
- Source: 4-traders;
- 591
- April 19, 2018
New Approvals rVWF VONVENDI VWD
Shire Announces Sale of Oncology Business to Servier for $2.4 Billion

Sale of Oncology business unlocks embedded value within Shire`s portfolio and sharpens focus on core areas reinforcing our leadership in rare diseases
- Source: finance.yahoo
- 657
- April 17, 2018
Company Insights oncology rare diseases
Takeda moots Shire move but big questions remain

Takeda is considering making a bold move for Shire, after announcing, as per UK regulations, that it may make an approach for the company.
- Source: takeda
- 643
- April 3, 2018
Company Insights Shire Takeda
Shire Reports Regulatory Milestones for Investigational Hereditary Angioedema (HAE) Treatment Lanadelumab

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for lanadelumab (SHP643) and also reports that Health Canada has completed screening and accepted the New Drug Submission (NDS) under Priority Review for this investigational compound.
- Source: Shire
- 613
- April 2, 2018
angioedema HAE lanadelumab New Approvals
Shire & NanoMedSyn Enter Collaboration

Shire and NanoMedSyn have entered into a preclinical research collaboration to evaluate a potential ERT using NanoMedSyn's proprietary synthetic derivatives named AMFA.
- Source: Contract Pharma
- 507
- March 27, 2018
preclinical Researches Shire
Priority review for Shire’s HAE drug

US regulators are undertaking a speedy review of Shire’s lanadelumab (SHP643) for the prevention of angioedema attacks in patients 12 years and older with hereditary angioedema (HAE).
- Source: pharmatimes
- 780
- February 24, 2018
angioedema HAE Market Views
Berkshire Hathaway, Amazon, chase partner to create healthcare company

It’s no secret Jeff Bezos has been looking to crack healthcare. But no one expected him to pull in Warren Buffett and Jamie Dimon, too.
- Source: Digital Insurance
- 433
- January 31, 2018
Company Insight healthcare

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.